AB0807 PATIENT-REPORTED OUTCOMES ABOUT QUALITY OF LIFE IN PATIENTS WITH IDIOPATHIC INFLAMMATION MYOPATHY
Authors: Z. Peng, Y. Wang, N. Liu, S. Zhou, J. L. Zhao, D. Xu, M. LI, C. Wu, X. Zeng, Q. Wang
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Idiopathic inflammation myopathy (IIM) defines a group of chronic autoimmune-mediated diseases that most commonly affect the skin, muscles, and lungs <sup>[1]</sup>. Despite considerable advances over the past decades in improving life expectancy<sub>,</sub> compared with the general population, IIM patients still experience substantially impaired health-related quality of life (HRQoL) <sup>[2]</sup>. The value of incorporating patient-reported outcomes in clinical trials is increasingly appreciated. The 36-item Short-Form Health Status Survey (SF-36) has been proposed to evaluate HR-QoL in IIM patients. However, because it is very time-consuming, the actual completion rate of the questionnaire is extremely low, and the SF-36 cannot be used directly in cost-effectiveness analyses. The EuroQol 5-Dimension (EQ-5D) is another tool for assessing HR-QoL and has been used extensively for chronic diseases. Wolfe et al. <sup>[3]</sup> verified the association between EQ-5D and SF-36 in rheumatic diseases. Moreover, workforce losses in patients with IIM are underestimated, and even health-related absenteeism imposes an economic burden on society <sup>[4]</sup>. <h3>Objectives</h3> To explore the feasibility and validity of the EuroQol 5-dimension (EQ-5D) and Work Productivity and Activity Impairment (WPAI) surveys as patient-reported outcomes of health-related quality of life (HR-QoL) in Idiopathic inflammation myopathy (IIM). <h3>Methods</h3> This cross-sectional study surveyed patient's outcomes using the Manual Muscle Testing-8 (MMT-8), Myositis Disease Activity Assessment Visual Analog Scale (MYOACT), Myositis Damage Index (MDI), Disease Activity Score (DAS), and Physician/Patient Global Assessment (PGA/PtGA). HR-QoL was determined using EQ-5D, 36-item Short-Form Health Status Survey (SF-36), and WPAI questionnaire. The relationship between IIM-related parameters and HR-QoL was assessed using ordinal logistic and quantile regression. <h3>Results</h3> We enrolled 189 patients with IIM. Decreased MMT-8 and increased MYOACT, DAS, MDI-global, and PGA/PtGA were associated with higher EQ-5D values. For the 25<sup>th</sup>–75<sup>th</sup> percentile of WPAI, greater activity impairment was associated with lower MMT-8 and higher age of onset and PGA. Poorer overall working productivity impairment was associated with higher MYOACT (cutaneous and skeletal). MDI-global and PtGA were associated with increased activity and overall working productivity impairment in most quantiles (<i>P</i> &lt; 0.05). <h3>Conclusion</h3> The EQ-5D and WPAI may be valid patient-reported outcomes to evaluate HR-QoL in ambulatory patients with IIM. <h3>References</h3> [1]Lundberg IE, Fujimoto M, Vencovsky J, Aggarwal R, Holmqvist M, Christopher-Stine L, et al. Idiopathic inflammatory myopathies. Nat Rev Dis Primers 2021;7(1):86. doi: 10.1038/s41572-021-00321-x, PMID 34857798. [2]Feldon M, Farhadi PN, Brunner HI, Itert L, Goldberg B, Faiq A, et al. Predictors of reduced health-related quality of life in adult patients with idiopathic inflammatory myopathies. Arthritis Care Res (Hoboken) 2017;69(11):1743-50. doi: 10.1002/acr.23198, PMID 28118525. [3]Wolfe F, Michaud K, Li T, Katz RS. EQ-5D and SF-36 quality of life measures in systemic lupus erythematosus: comparisons with rheumatoid arthritis, noninflammatory rheumatic disorders, and fibromyalgia. J Rheumatol 2010;37(2):296-304. doi: 10.3899/jrheum.090778, PMID 20032098. [4]Bradford Rice J, White A, Lopez A, Galebach P, Schepman P, Popelar B, et al. Healthcare resource utilization and work loss in dermatomyositis and polymyositis patients in a privately-insured US population. J Med Econ 2016;19(7):649-54. doi: 10.3111/13696998.2016.1151433, PMID 26850074. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.